Primary Hemostasis in Chronic Liver Disease and Cirrhosis: What Did We Learn over the Past Decade?

Area of Science:

• Hepatology
• Hematology
• Thrombosis and Hemostasis

Background:

• Chronic liver disease (CLD) and cirrhosis present complex hemostatic challenges.
• Thrombocytopenia and platelet dysfunction are common but primary hemostasis often remains balanced.
• Patients face risks of both bleeding and clotting complications.

Purpose of the Study:

• To review recent literature on primary hemostasis in CLD and cirrhosis.
• To discuss platelet count, function, and the role of thrombopoietin agonists.
• To examine von Willebrand factor and global hemostasis tests in this context.

Main Methods:

• Literature review of studies published in the past decade.
• Analysis of platelet count and thrombopoietin (TPO) agonist efficacy.
• Evaluation of platelet function tests and activation markers.
• Assessment of von Willebrand factor and global hemostasis assays.

Main Results:

• Thrombocytopenia in CLD is multifactorial, yet primary hemostasis is often preserved.
• Variceal bleeding is primarily linked to portal hypertension, not hemostatic failure.
• Thrombopoietin agonists show promise in managing thrombocytopenia for invasive procedures.

Conclusions:

• Primary hemostasis in CLD is a delicate balance, not solely dictated by platelet count.
• Understanding platelet function and hemostatic markers is crucial for managing CLD patients.
• Further research on thrombopoietin agonists and hemostatic profiles is warranted.